CoChat

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants

Open access

The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are the class of antiretroviral (ARV) drugs most recently approved by the FDA for the treatment of HIV-1 infections. INSTIs block the strand transfer reaction catalyzed by HIV-1 integrase (IN) and have been shown to potently inhibit infection by wild-type HIV-1. Of the three current FDA-approved INSTIs, Dolutegravir (DTG), has been the most effective, in part because treatment does not readily select for resistant mutants. However, recent studies showed that when INSTI-experienced patients are put on a DTG-salvage therapy, they have reduced response rates. Two new INSTIs, Cabotegravir (CAB) and Bictegravir (BIC), are currently in late-stage clinical trials. RESULTS: Both CAB and BIC had much broader antiviral profiles than RAL and EVG against the INSTI-resistant single, double, and triple HIV-1 mutants used in this study. BIC was more effective than DTG against several INSTI-resistant mutants. Overall, in terms of their ability to inhibit a broad range of INSTI-resistant IN mutants, BIC was superior to DTG, and DTG was superior to CAB. Modeling the binding of CAB, BIC, and DTG within the active site of IN suggested that the "left side" of the INSTI pharmacophore (the side away from the viral DNA) was important in determining the ability of the compound to inhibit the IN mutants we tested. CONCLUSIONS: Of the two INSTIs in late stage clinical trials, BIC appears to be better able to inhibit the replication of a broad range of IN mutants. BIC retained potency against several of the INSTI-resistant mutants that caused a decrease in susceptibility to DTG.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12977-018-0420-7

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Chemical structures of INSTIs. The chemical structures of RAL, EVG, DTG, BIC, and CAB are shown
Fig. 1 Chemical structures of INSTIs. The chemical structures of RAL, EVG, DTG, BIC, and CAB are shownCC BY · PubMed Central
Fig. 2 Antiviral activities of BIC and CAB against primary INSTI-resistant mutants. The EC50 values were determined, in single round infection assays, using vectors that carry the INSTI-resistant IN mutants. Error bars represent the standard deviations in the data from independent experiments (n = 4). The EC50 values shown in the figure have a maximum of 100 nM. The EC50 values of RAL against Y143R, N155H, and G140S/Q148H, EVG versus G140S/Q148H, and E92Q primary INSTI-resistant mutants were all > 100 nM
Fig. 2 Antiviral activities of BIC and CAB against primary INSTI-resistant mutants. The EC50 values were determined, in single round infection assays, using vectors that carry the INSTI-resistant IN mutants. Error bars represent the standard deviations in the data from independent experiments (n = 4). The EC50 values shown in the figure have a maximum of 100 nM. The EC50 values of RAL against Y143R, N155H, and G140S/Q148H, EVG versus G140S/Q148H, and E92Q primary INSTI-resistant mutants were all > 100 nMCC BY · PubMed Central
Fig. 3 Statistical significance of the antiviral data among DTG, CAB, and BIC. The Student’s t test was used to calculate the statistical significance of the differences in the antiviral activities of the INSTIs. Because of multiple comparisons, p values < 0.025 were considered statistically significant when comparing the efficacies among DTG, CAB, and BIC
Fig. 3 Statistical significance of the antiviral data among DTG, CAB, and BIC. The Student’s t test was used to calculate the statistical significance of the differences in the antiviral activities of the INSTIs. Because of multiple comparisons, p values < 0.025 were considered statistically significant when comparing the efficacies among DTG, CAB, and BICCC BY · PubMed Central
Fig. 4 Antiviral activities of BIC and CAB against common INSTI-resistant single mutants. The EC50 values were determined using vectors that carry the INSTI-resistant IN double mutants in single round infection assays. Error bars represent the standard deviations in the data from independent experiments (n = 4). The EC50 values shown in the figure have a maximum of 100 nM. The EC50 values of RAL against Q148H, Q148K, and Q148R and EVG versus Q148K and Q148R INSTI-resistant mutants were all > 100 nM
Fig. 4 Antiviral activities of BIC and CAB against common INSTI-resistant single mutants. The EC50 values were determined using vectors that carry the INSTI-resistant IN double mutants in single round infection assays. Error bars represent the standard deviations in the data from independent experiments (n = 4). The EC50 values shown in the figure have a maximum of 100 nM. The EC50 values of RAL against Q148H, Q148K, and Q148R and EVG versus Q148K and Q148R INSTI-resistant mutants were all > 100 nMCC BY · PubMed Central
Fig. 5 Antiviral activities of BIC and CAB against a panel of INSTI-resistant double mutants that have a primary mutation at position Q148. The EC50 values were determined using vectors that carry the INSTI-resistant double mutants in single round infection assays. Error bars represent the standard deviations in the data from independent experiments (n = 4). The EC50 values shown in the figure have a maximum of 100 nM. The EC50 values of RAL and EVG against this entire panel (except for EVG versus Y143R/Q148H) were all > 100 nM. The EC50 values of DTG against G140A/Q148K, CAB versus E138K/Q148K, G140A/Q148K, G140S/Q148R, and BIC against G140A/Q148K were all > 100 nM
Fig. 5 Antiviral activities of BIC and CAB against a panel of INSTI-resistant double mutants that have a primary mutation at position Q148. The EC50 values were determined using vectors that carry the INSTI-resistant double mutants in single round infection assays. Error bars represent the standard deviations in the data from independent experiments (n = 4). The EC50 values shown in the figure have a maximum of 100 nM. The EC50 values of RAL and EVG against this entire panel (except for EVG versus Y143R/Q148H) were all > 100 nM. The EC50 values of DTG against G140A/Q148K, CAB versus E138K/Q148K, G140A/Q148K, G140S/Q148R, and BIC against G140A/Q148K were all > 100 nMCC BY · PubMed Central
Fig. 6 Antiviral activities of BIC and CAB against a panel of INSTI-resistant double mutants that included the primary mutations T66I and N155H with additional mutations at other positions. The EC50 values were determined using vectors that carry the INSTI-resistant double mutants in single round infection assays. Error bars represent the standard deviations in the data from independent experiments (n = 4). The EC50 values shown in the figure have a maximum of 100 nM. The EC50 values of RAL against this entire panel of INSTI-resistant double mutants were all > 100 nM. The EC50 values of EVG against E92Q/N155H and Y143R/N155H were all > 100 nM
Fig. 6 Antiviral activities of BIC and CAB against a panel of INSTI-resistant double mutants that included the primary mutations T66I and N155H with additional mutations at other positions. The EC50 values were determined using vectors that carry the INSTI-resistant double mutants in single round infection assays. Error bars represent the standard deviations in the data from independent experiments (n = 4). The EC50 values shown in the figure have a maximum of 100 nM. The EC50 values of RAL against this entire panel of INSTI-resistant double mutants were all > 100 nM. The EC50 values of EVG against E92Q/N155H and Y143R/N155H were all > 100 nMCC BY · PubMed Central
Fig. 7 Overall Comparison of the statistical significance of the antiviral data among DTG, CAB, and BIC. The Student’s t test was used to calculate the statistical significance of the differences in the antiviral activities of the INSTIs. The p values < 0.025, < 0.01, and < 0.001 between DTG, CAB, and BIC were used to decide which INSTIs were more broadly efficacious against the mutants
Fig. 7 Overall Comparison of the statistical significance of the antiviral data among DTG, CAB, and BIC. The Student’s t test was used to calculate the statistical significance of the differences in the antiviral activities of the INSTIs. The p values < 0.025, < 0.01, and < 0.001 between DTG, CAB, and BIC were used to decide which INSTIs were more broadly efficacious against the mutantsCC BY · PubMed Central
Fig. 8 Antiviral activities of BIC and CAB against a panel INSTI-resistant triple mutants that included a primary mutation (Q148H/K/R) and two additional mutations. The EC50 values were determined using vectors that carry the INSTI-resistant triple mutants in single round infection assays. Error bars represent the standard deviations in the data from independent experiments (n = 4). The EC50 values shown in the figure have a maximum of 100 nM. The EC50 values of RAL and EVG versus this entire panel of INSTI-resistant triple mutants were all > 100 nM. The EC50 values of DTG against E138K/G140A/Q148K, CAB versus E138K/G140A/Q148K, L74M/G140C/Q148R, and E138K/G140C/Q148R, and BIC against E138K/G140A/Q148K were all > 100 nM
Fig. 8 Antiviral activities of BIC and CAB against a panel INSTI-resistant triple mutants that included a primary mutation (Q148H/K/R) and two additional mutations. The EC50 values were determined using vectors that carry the INSTI-resistant triple mutants in single round infection assays. Error bars represent the standard deviations in the data from independent experiments (n = 4). The EC50 values shown in the figure have a maximum of 100 nM. The EC50 values of RAL and EVG versus this entire panel of INSTI-resistant triple mutants were all > 100 nM. The EC50 values of DTG against E138K/G140A/Q148K, CAB versus E138K/G140A/Q148K, L74M/G140C/Q148R, and E138K/G140C/Q148R, and BIC against E138K/G140A/Q148K were all > 100 nMCC BY · PubMed Central
Fig. 9 Antiviral activities of BIC and CAB versus a panel of INSTI-resistant triple mutants that consists of a primary mutation at T66I and N155H with additional secondary mutations. The EC50 values were determined using vectors that carry the INSTI-resistant triple mutants in single round infection assays. Error bars represent the standard deviations of the data from independent experiments (n = 4). The EC50 value shown in the figure have a maximum of 100 nM. The EC50 values of RAL against T97A/Y143R/N155H, G140S/Y143R/N155H, and E92Q/N155H/G163R were all > 100 nM. The EC50 values of EVG versus T97A/Y143R/N155H and E92Q/N155H/G163R and CAB against T97A/Y143R/N155H were all > 100 nM
Fig. 9 Antiviral activities of BIC and CAB versus a panel of INSTI-resistant triple mutants that consists of a primary mutation at T66I and N155H with additional secondary mutations. The EC50 values were determined using vectors that carry the INSTI-resistant triple mutants in single round infection assays. Error bars represent the standard deviations of the data from independent experiments (n = 4). The EC50 value shown in the figure have a maximum of 100 nM. The EC50 values of RAL against T97A/Y143R/N155H, G140S/Y143R/N155H, and E92Q/N155H/G163R were all > 100 nM. The EC50 values of EVG versus T97A/Y143R/N155H and E92Q/N155H/G163R and CAB against T97A/Y143R/N155H were all > 100 nMCC BY · PubMed Central
Fig. 10 Antiviral activities of CAB and BIC against a panel of INSTI-resistant triple mutants that include the well-characterized RAL-resistant double mutant G140S/Q148H plus an additional secondary mutation. The EC50 values were determined using vectors that carry the INSTI-resistant triple mutants in single round infection assays. Error bars represent the standard deviations in the data from independent experiments (n = 4). The EC50 values shown in the figure have a maximum of 100 nM. The EC50 values of RAL and EVG against this entire panel of INSTI-resistant triple mutants were all > 100 nM. The EC50 values of CAB against G140S/Y143R/Q148H and G140S/Q148H/N155H were all > 100 nM
Fig. 10 Antiviral activities of CAB and BIC against a panel of INSTI-resistant triple mutants that include the well-characterized RAL-resistant double mutant G140S/Q148H plus an additional secondary mutation. The EC50 values were determined using vectors that carry the INSTI-resistant triple mutants in single round infection assays. Error bars represent the standard deviations in the data from independent experiments (n = 4). The EC50 values shown in the figure have a maximum of 100 nM. The EC50 values of RAL and EVG against this entire panel of INSTI-resistant triple mutants were all > 100 nM. The EC50 values of CAB against G140S/Y143R/Q148H and G140S/Q148H/N155H were all > 100 nMCC BY · PubMed Central
Fig. 11 Modeling BIC and CAB into the PFV Intasome. The four panels show models of DTG, CAB, or BIC bound in the active site of HIV-1 IN. The upper left panel a shows a model of DTG (cyan) bound to HIV-1 IN. The upper right panel b shows a model of CAB (green) bound to the active site of the HIV-1 IN using DTG (cyan) as the template. The lower left panel c shows a model of BIC (magenta) bound to the active site of HIV-1 IN using DTG (cyan) as the template. The lower right panel d shows an overlay of the binding of DTG (cyan), BIC (magenta), and CAB (green) to HIV-1 IN, specifically showing how the “left-side” of these three INSTIs, the part of pharmacophores distal from the end of the viral DNA, interact with HIV-1 IN. All four panels show the Mg2+ cofactors rendered in space-filling format (slate gray) interacting with the chelating motifs of each of the INSTIs. HIV-1 IN is depicted in multi-colored ribbons with active site residues D64, D116, and E152 labeled in red and rendered in dark gray ball and stick format
Fig. 11 Modeling BIC and CAB into the PFV Intasome. The four panels show models of DTG, CAB, or BIC bound in the active site of HIV-1 IN. The upper left panel a shows a model of DTG (cyan) bound to HIV-1 IN. The upper right panel b shows a model of CAB (green) bound to the active site of the HIV-1 IN using DTG (cyan) as the template. The lower left panel c shows a model of BIC (magenta) bound to the active site of HIV-1 IN using DTG (cyan) as the template. The lower right panel d shows an overlay of the binding of DTG (cyan), BIC (magenta), and CAB (green) to HIV-1 IN, specifically showing how the “left-side” of these three INSTIs, the part of pharmacophores distal from the end of the viral DNA, interact with HIV-1 IN. All four panels show the Mg2+ cofactors rendered in space-filling format (slate gray) interacting with the chelating motifs of each of the INSTIs. HIV-1 IN is depicted in multi-colored ribbons with active site residues D64, D116, and E152 labeled in red and rendered in dark gray ball and stick formatCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 128

Metadata

Authors
Smith, S. J., Zhao, X. Z., Burke, T. R., & Hughes, S. H.
Affiliations
National Institutes of Health (US)
Corresponding author
Hughes, Stephen H.
Venue
Retrovirology
Published
2018-05-16
Volume
15
Issue
1
Pages
37-37
ISSN
1742-4690 (ISSN-L)
OpenAlex
W2804301217
Cited by
114
References
58
Citations by year
2026: 7 · 2025: 8 · 2024: 7 · 2023: 9 · 2022: 20 · 2021: 17 · 2020: 22 · 2019: 15 · 2018: 8
FWCI
11.70
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Retrovirology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Cancer Institute
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Keywords
cabotegravir, bictegravir, dolutegravir, HIV-1 integrase, integrase strand transfer inhibitors, antiviral activity, integrase inhibitors
MeSH terms
Amides, Cell Line, Codon, Heterocyclic Compounds, 3-Ring, Heterocyclic Compounds, 4 or More Rings, Humans, Microbial Sensitivity Tests, Models, Molecular, Molecular Conformation, Mutation, Piperazines, Pyridones, Structure-Activity Relationship, Virus Replication, HIV-1, HIV Infections, HIV Integrase, HIV Integrase Inhibitors, Drug Resistance, Viral, Diketopiperazines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants. https://app.cochat.ai/papers/10.1186/s12977-018-0420-7
The paper
Smith, S. J., Zhao, X. Z., Burke, T. R., & Hughes, S. H. (2018). Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. https://doi.org/10.1186/s12977-018-0420-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.